NCT07447817
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Start date: May 4, 2026 to Oct 23, 2026
- Eligibility criteria expanded, about 40 words
- Secondary endpoints: details revised at 6 of 10 entries
- Site details revised at 3 of 3 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change in spleen volume
Timeframe: Baseline and 24 weeks
Secondary (10)
Spleen response rate
Change in the Myelofibrosis-Symptom Assessment Form Total Symptom Score (MF-SAF TSS)
Change in Patient Global Impression of Change (PGIC)
Anemia response
Change in hemoglobin level
Show 5 moreShow less
Change in platelet count
Progression-free survival
Overall survival
Number of participants achieving RBC transfusion independence)
Number of participants achieving platelet transfusion independence
Arms and interventions
Pacritinib/SelinexorExperimental
Study participants will receive pacritinib monotherapy (200mg BID orally) for the first cycle (28 days). If they qualify to add on selinexor at any point from Cycle 2 Day 1 to Cycle 4 Day 1, participants will have selinexor (60mg QW orally) added onto their pacritinib regimen.
Drugs: Pacritinib, Selinexor
Sites
3 sites in 1 country